Facial Injectable Global Market Report 2022: Sector to Reach $23.55 Billion by 2027 at a 15.46% CAGR

Rhea-AI Summary

The facial injectable market was valued at US$8.606 billion in 2020, projected to reach US$23.549 billion by 2027 with a CAGR of 15.46%. This growth is driven by an aging population and rising interest in minimally invasive procedures. Market players like Revance Therapeutics, Inc. (RVNC) are capitalizing on this trend, having signed a U.S. distribution agreement with TEOXANE SA to market their hyaluronic acid fillers. The FDA is reviewing DaxibotulinumtoxinA Injection, signifying ongoing innovation. Despite this growth, challenges include potential adverse effects and regulatory issues surrounding botulinum toxin use.

Positive

• Facial injectable market projected to reach US$23.549 billion by 2027.
• CAGR of 15.46% indicates strong growth potential.
• Revance Therapeutics signed a U.S. distribution agreement with TEOXANE SA.
• FDA review of DaxibotulinumtoxinA Injection suggests ongoing innovation.

Negative

• Adverse effects like allergic reactions may impede market growth.
• Regulatory issues surrounding botulinum toxin type A could pose challenges.

DUBLIN, Feb. 28, 2023 /PRNewswire/ -- The "Facial Injectable Market - Forecasts from 2022 to 2027" report has been added to  ResearchAndMarkets.com's offering.

The facial injectable market was evaluated at US$8.606 billion in the year 2020, growing at a CAGR of 15.46% reaching the market size of US$23.549 billion by the year 2027.

Products about facial injectables also referred to as dermal fillers, are intended to reconstruct and bioengineer facial features for facial rejuvenation to rectify wrinkles caused due to the loss of subcutaneous fat over the face that is experienced by individuals as they grow old. The products are necessary for treating early signs of ageing or complementing facial rejuvenation surgery.

Additionally, the growing consciousness about appearance, along with the increasing pool of the geriatric population, is the primary driver estimated to catapult the facial injectable market to new heights during the forecast period. Moreover, the increasing shift towards minimally invasive procedures and continuous development in glacial rejuvenation is expected to augment the growth of the same market further.

Additionally, the rising awareness regarding the accessibility of various products and procedures, which has stemmed due to the increasing number of players entering the facial injectables space across the globe, will aid the market growth.

Further, the individualistic value-driven rationale has superseded the generic mob mentality of yesteryears which incentivizes today's consumers to look for products that are more oriented to themselves.

Moreover, this interest has also fueled investments in various research studies like that of DREAM (Dysport Real-world Evaluation and Measured satisfaction study) carried out by Galderma, after which, in May 2020, it announced that 95% of patients treated with Dysport achieved high levels of satisfaction with two treatments per year, and 97% of patients believed the result of the treatment looked natural.

In the same year, HUONS announced that the Korean Ministry of Food and Drug Safety had given it the approval to conduct phase 2 clinical trials for Liztox, its independently developed botulinum toxin (BTX) product launched in June 2019, for treating square jaws. Moreover, from the perspective of increasing market reach, in 2020, Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering innovations in neuromodulators for aesthetic and therapeutic indications, announced the signing of a U.S. distribution agreement with TEOXANE SA.

The Resilient Hyaluronic Acid technology from the Swiss company will be exclusively commercialized by Revance under the terms of this agreement. The RHA series of fillers from TEOXANE includes lidocaine-containing RHA 2, RHA 3, and RHA 4 formulations that have received FDA approval. The RHA line was designed using a patented crosslinking method that preserves the hyaluronic acid network to correct moderate-to-severe dynamic facial wrinkles and folds, optimizing strength, stretch, and tissue integration. It provides physicians with a broad range of uniquely designed gels for individualized treatment of the face.

Further, due to the upward trend, there has been a new development in the aesthetics armlet, particularly that of the Facial Injectable market. For instance, Galderma announced that "Restylane Kysse" - its lip filler lip augmentation product, received FDA. Again, Revance Therapeutics, Inc recently announced that the Biologics License Application (BLA) for DaxibotulinumtoxinA Injection (DAXI), which is its next-generation neuro modular product aimed at treating moderate to severe frown lines, has been accepted for review by the U.S. Food and Drug Administration (FDA). In 2019 The HydraFacialT Company announced that it had entered into a partnership with Advanced Dermatology and Cosmetic Surgery, the largest dermatology practice in the United States.

Additionally, Juvederm VOLUMA XC, a hyaluronic acid gel dermal filler, was approved by the U.S. Food and Drug Administration (FDA) for use with a TSK STERiGLIDETM cannula for cheek augmentation to treat age-related volume deficit in the mid-face in people over the age of 21. Thus, from those mentioned above, it is evident that the facial injectable market is expected to witness a significant rise during the forecast period. Nevertheless, certain adverse effects, viz. allergic reactions, nausea, skin rash, as well as neck and back pain, are expected to deter the growth. Further regularity issues about botulinum toxin type A are also expected to pose a hindrance to market growth during the forthcoming years.

Recent Developments and expansions

• Sinclair Pharma offered Galderma SA distribution partnership rights for Sculptra a poly-I-Iatic acid injectable in February 2020, with a focus on Europe.
• One of the major players, Allergan, started a TV advertising campaign for their brand, Botox Cosmetics, targeted at millennials in 2019. The American Academy of Facial Plastic & Reconstructive Surgery reports that among those aged 22 to 37, the target market for the company's new product, Botox injections has climbed by 22% over the previous five years.
• FDA authorization for JUVEDERM VOLUMA XC for the enhancement of the chin region in people over the age of 21 was granted to Allergan Aesthetics in June 2020, a division of AbbVie Inc.

Segmentation
By Product Type

• Botulinum Toxin
• Collagen
• Hyaluronic Acid
• Particle & Polymer Fillers (PPF)
• Calcium Hydroxyapatite
• Poly-l-Lactic Acid
• Polymethylmethacrylate

By Application

• Aesthetics
• Therapeutics

By End-Users

• Dermatology & Beauty Clinics
• Hospitals
• Research Institutes

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Middle East and Africa
• UAE
• Saudi Arabia
• Asia Pacific
• China
• Japan
• South Korea
• India
• Thailand
• Indonesia

Companies Mentioned

• Allergan (AbbVie Inc)
• Bausch Health Companies Inc.
• Bloomage Biotechnology Corporation Limited
• Galderma
• Ispen Biopharmaceuticals Inc
• Merz Pharma
• Prollenium Medical Technologies
• Sanofi
• Sinclair Pharma
• Suneva Medical

For more information about this report visit https://www.researchandmarkets.com/r/yf604h-injectable?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood |

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/facial-injectable-global-market-report-2022-sector-to-reach-23-55-billion-by-2027-at-a-15-46-cagr-301758638.html

SOURCE Research and Markets

FAQ

What is the forecast for the facial injectable market size by 2027?

The facial injectable market is projected to reach US$23.549 billion by 2027.

What is the CAGR for the facial injectable market?

The market is expected to grow at a CAGR of 15.46% from 2020 to 2027.

What recent agreement did Revance Therapeutics enter regarding facial injectables?

Revance Therapeutics entered a U.S. distribution agreement with TEOXANE SA for hyaluronic acid fillers.

What FDA action is Revance Therapeutics awaiting for its product?

Revance Therapeutics is awaiting FDA review of its DaxibotulinumtoxinA Injection.

What challenges does the facial injectable market face?

The market faces challenges from potential adverse effects and regulatory issues related to botulinum toxin.